Verrica Pharmaceuticals (VRCA) News Today → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Buy VRCA with Qtrade Free VRCA Stock Alerts $8.84 +0.17 (+1.96%) (As of 11:19 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15, 2024 | markets.businessinsider.comVerrica Pharma Enters Amendment To License Agreement With Torii PharmaMay 15, 2024 | finance.yahoo.comVerrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common WartsMay 15, 2024 | globenewswire.comVerrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common WartsMay 15, 2024 | americanbankingnews.comVerrica Pharmaceuticals (NASDAQ:VRCA) PT Raised to $14.00 at HC WainwrightMay 15, 2024 | americanbankingnews.comVerrica Pharmaceuticals (NASDAQ:VRCA) Price Target Raised to $16.00May 14, 2024 | msn.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comVerrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verrica Pharmaceuticals on Strong Ycanth Sales and Strategic Growth ProspectsMay 13, 2024 | markets.businessinsider.comStrong Buy Rating for Verrica Pharmaceuticals as Ycanth Launch Exceeds ExpectationsMay 13, 2024 | finanznachrichten.deVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 13, 2024 | finance.yahoo.comVerrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial ReviewMay 13, 2024 | globenewswire.comVerrica Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 12, 2024 | markets.businessinsider.comHere's what Wall Street expects from Verrica Pharmaceuticals's earningsMay 11, 2024 | americanbankingnews.comVerrica Pharmaceuticals (VRCA) to Release Earnings on MondayMay 11, 2024 | msn.comVerrica Pharmaceuticals to Discuss Q1 Financial Results in Upcoming WebcastMay 9, 2024 | globenewswire.comVerrica Pharmaceuticals to Present at Upcoming Investor ConferencesMay 8, 2024 | globenewswire.comVerrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024May 3, 2024 | seekingalpha.comVRCA Verrica Pharmaceuticals Inc.April 19, 2024 | investing.comVerrica Pharmaceuticals Inc (VRCA)April 10, 2024 | marketbeat.comNeedham & Company LLC Reiterates "Buy" Rating for Verrica Pharmaceuticals (NASDAQ:VRCA)Needham & Company LLC restated a "buy" rating and set a $8.00 target price on shares of Verrica Pharmaceuticals in a research report on Wednesday.April 4, 2024 | msn.comVerrica Pharmaceuticals to Spotlight Innovations at Needham Healthcare ConferenceApril 3, 2024 | finance.yahoo.comStrong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year lossApril 2, 2024 | globenewswire.comVerrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 31, 2024 | msn.comVerrica Pharmaceuticals Secures Key FDA Designation for YCANTH, Enhancing Market ProtectionMarch 28, 2024 | finanznachrichten.deVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDAMarch 27, 2024 | msn.comVerrica Pharma gains as FDA lists Ycanth in Orange BookMarch 26, 2024 | markets.businessinsider.comVerrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick FactsMarch 26, 2024 | globenewswire.comVerrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDAMarch 9, 2024 | marketbeat.comFmr LLC Has $5.85 Million Position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)Fmr LLC lifted its holdings in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Free Report) by 29.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,504,716 shares of the company's stock after purchasing an additional 341,584 shares during the quarter. Fmr LLCMarch 3, 2024 | msn.comVerrica Pharmaceuticals Set to Illuminate TD Cowen Healthcare Conference with Fireside ChatMarch 2, 2024 | finance.yahoo.comVerrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineMarch 2, 2024 | finance.yahoo.comWhen Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?March 1, 2024 | finanznachrichten.deVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 1, 2024 | markets.businessinsider.comVerrica Pharmaceuticals Outperforms with YCANTH Sales, Promising Outlook Spurs Buy RatingMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market ExpansionMarch 1, 2024 | finance.yahoo.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | marketbeat.comVerrica Pharmaceuticals (NASDAQ:VRCA) PT Raised to $13.00HC Wainwright boosted their price target on Verrica Pharmaceuticals from $12.00 to $13.00 and gave the stock a "buy" rating in a research report on Friday.March 1, 2024 | marketbeat.comVerrica Pharmaceuticals (NASDAQ:VRCA) Receives "Buy" Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $8.00 price objective on shares of Verrica Pharmaceuticals in a research note on Friday.February 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verrica Pharmaceuticals Amidst Promising Ycanth Launch and Market AcceptanceFebruary 29, 2024 | finance.yahoo.comVerrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial ResultsFebruary 29, 2024 | globenewswire.comVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial ResultsFebruary 28, 2024 | benzinga.comEarnings Outlook For Verrica PharmaceuticalsFebruary 27, 2024 | globenewswire.comVerrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare ConferenceFebruary 23, 2024 | marketbeat.comVerrica Pharmaceuticals (VRCA) Set to Announce Quarterly Earnings on ThursdayVerrica Pharmaceuticals (NASDAQ:VRCA) will be releasing earnings before the market opens on Thursday, February 29, Zacks reports.February 22, 2024 | finance.yahoo.comVerrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024February 22, 2024 | globenewswire.comVerrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024February 13, 2024 | marketbeat.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Large Decrease in Short InterestVerrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) saw a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 4,430,000 shares, a drop of 20.2% from the January 15th total of 5,550,000 shares. Currently, 17.7% of the company's shares are short sold. Based on an average daily volume of 1,090,000 shares, the days-to-cover ratio is currently 4.1 days.February 12, 2024 | msn.comVerrica Pharmaceuticals (NASDAQ:VRCA) Is Egging on Contrarian Options TradersFebruary 6, 2024 | finance.yahoo.com7 Potential Short-Squeeze Stocks Poised for Rapid GainsFebruary 5, 2024 | bizjournals.comVerrica Pharmaceuticals sues Canadian drug maker, alleging false advertising and unfair competition Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Email Address This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world. Click here to learn more about the booming eHealth industry VRCA Media Mentions By Week VRCA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRCA News Sentiment▼0.540.42▲Average Medical News Sentiment VRCA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRCA Articles This Week▼122▲VRCA Articles Average Week Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VTYX News KMDA News ORGO News CRMD News NLTX News VNDA News AVIR News URGN News NKTX News PROC News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRCA) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldUrgent Nvidia WarningAltimetryDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyShocking: One AI startup's revenue could surge 4,735%Manward PressThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
